Product Details
| Product Name:
Irosustat |
CAS No.:
288628-05-7 |
| Purity:
98.76% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Irosustat |
| Description | Irosustat (667-Coumate) is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity. |
| Cell Research | MCF-7 cells are cultured in growth medium (minimum essential medium (MEM) containing, phenol red, 10% foetal calf serum (FCS) and essential nutrients). When the cells reach 60% confluency, they are treated with Irosustat (0.001-10 μM) in growth medium. After 72 h of incubation, photographs are taken under normal conditions of light and the number of attached cells in each flask is determined using a Coulter cell counter |
| Animal Research | Irosustat is formulated in propylene glycol.RatsLudwig rats bearing mammary tumors are used in the assay. Tumor development is monitored, and animals are ovariectomized when tumors reach 0.8-1.5 cm in diameter. Tumors are allowed to regress over a 12- to 13-day period to confirm their hormone-dependent status. Regrowth of tumors is stimulated with oestrone sulfate (E1S; 50 μg/day, s.c.). When tumors have regrown, animals continue to receive either E1S alone or E1S plus Irosustat at 10 mg/kg/day or 2 mg/kg/day, p.o., until tumor regression has occurred. Tumor volumes are calculated from two measured diameters. |
| In vitro | Irosustat (667 COUMATE), a potent steroid sulfatase inhibitor, exhibits an IC50 of 8 nM and inhibits steroid sulfatase (STS) activity in MCF-7 cells with an IC50 of 0.2 nM, without affecting the morphology or proliferation of MCF-7 cells at 10 μM. |
| In vivo | Irosustat effectively inhibits over 90% of rat liver activity at a concentration of 1 mg/kg. At doses of 2 mg/kg administered orally for five days, it impedes uterine growth induced by oestrone sulfate (E1S) in ovariectomized rats. Additionally, when combined with E1S, Irosustat, at dosages of 2 and 10 mg/kg administered orally, reduces the growth of NMU-induced mammary tumors in these rats in a dose-dependent manner. Moreover, at a dosage of 10 mg/kg administered orally, Irosustat (identified as 667 COUMATE) achieves a 97.9 ± 0.06% inhibition of steroid sulphatase (STS) activity in rat liver. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (177.8 mM)
|
| Keywords | Inhibitor | BN-83495 | Irosustat | inhibit | STX 64 | STX-64 | BN 83495 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:70-00-8
$30.00 / 10mg
-
CAS:1346528-50-4
$38.00 / 2mg
-
CAS:93479-97-1
$54.00 / 500mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States